To ask the Scottish Government, in the light of the recommendation in the review by Dr Brian Montgomery that managed access schemes should be developed as an additional option rather than a replacement for patient access schemes, what the principles are for development of new processes; what types of schemes are being considered and what level of flexibility is being built-in to improve access and affordability of innovative new medicines.